{'final_output': 'The best clinical trial for the patient is the Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma. The patient meets all of the eligibility criteria and the intervention could be a good fit for their condition as it is a form of radiation therapy followed by surgery. The second clinical trial, Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study, is not a good fit for the patient as they do not meet the age criteria. The final answer is the actual complete content as the final answer, not a summary.', 'tasks_outputs': [TaskOutput(description="ASK THE HUMAN for their mediacl diagnosis. Extract keywords from the human's medical condition description.", summary='ASK THE HUMAN for their mediacl diagnosis. Extract keywords from...', exported_output='sarcoma', raw_output='sarcoma'), TaskOutput(description='Search for clinical trials using the extracted keywords.\n  ', summary='Search for clinical trials using the extracted keywords.\n  ...', exported_output='[{\'officialTitle\': \'Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma\', \'eligibilityModule\': {\'eligibilityCriteria\': \'Inclusion Criteria:\\n\\n1. AJCC 8th edition stage I-III histologically confirmed STS of the extremity or trunk\\n2. Male or female, aged > 18 years old\\n3. ECOG Performance Status 0-3\\n4. Meets screening criteria for receipt of radiotherapy\\n5. Deemed eligible for wide local excision\\n\\nExclusion Criteria:\\n\\n1. Distant metastatic disease\\n2. Prior radiation therapy in the proposed treatment area\\n3. Simultaneous treatment of another malignancy\\n4. Planned neoadjuvant or adjuvant chemotherapy\', \'healthyVolunteers\': False, \'sex\': \'ALL\', \'minimumAge\': \'18 Years\', \'stdAges\': [\'ADULT\', \'OLDER_ADULT\']}, \'centralContacts\': [{\'name\': \'Alan Brisendine\', \'role\': \'CONTACT\', \'phone\': \'843-792-9007\', \'email\': \'brisend@musc.edu\'}, {\'name\': \'Jasmin M Brooks\', \'role\': \'CONTACT\', \'email\': \'brooksjm@musc.edu\'}], \'conditions\': [\'Soft Tissue Sarcoma\'], \'armsInterventionsModule\': {\'armGroups\': [{\'label\': \'Hypofractionated Radiation Therapy\', \'type\': \'EXPERIMENTAL\', \'interventionNames\': [\'Radiation: Hypofractionated Radiation Therapy\']}], \'interventions\': [{\'type\': \'RADIATION\', \'name\': \'Hypofractionated Radiation Therapy\', \'description\': \'Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by "standard of care" wide local excision 2-6 weeks later.\', \'armGroupLabels\': [\'Hypofractionated Radiation Therapy\']}]}, \'outcomesModule\': {\'primaryOutcomes\': [{\'measure\': \'Feasibility of 5-day HFRT\', \'description\': \'The preoperative 5-day HFRT uptake rate, defined as the proportion of eligible patients who elect to participate in the trial.\', \'timeFrame\': \'Up to 3 years\'}], \'secondaryOutcomes\': [{\'measure\': \'Rate of favorable pathologic response\', \'description\': \'Proportion of patients with extent of tumor fibrosis/hyalinization and infarct > 12.5%\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Rate of major wound complication\', \'description\': \'Major wound complication defined according to CAN-NCIC-SR2 Multi-center trial within 6 months of surgery\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Local Control\', \'description\': \'Local control defined as 1-year Local Recurrence Free Survival, calculated from the date of surgery to the date of 12-month follow up\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Acute toxicity\', \'description\': \'Acute toxicity defined by CTCAE v 5.0 assessed during radiotherapy treatment and 2 weeks following completion of radiotherapy\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'1-year late HFRT toxicity\', \'description\': \'Defined by physician assessment using the RTOG/EORTC criteria and the Stern scale for edema\', \'timeFrame\': \'Up to 3 years\'}], \'otherOutcomes\': [{\'measure\': \'Comparison of socio-demographic profiles\', \'description\': \'age, race, gender, marital status, health insurance status, comorbidities, geocode defined rural vs urban residence, estimated distance traveled to HCC, census tract level American Community Survey variables to include Socioeconomic status, Household Composition and Disability, Minority Status and Language, Housing Type, and Transportation\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Comparison of retention rate for radiotherapy at the clinical site\', \'description\': \'number of patients meeting trial eligibility criteria in prior 3 years that received radiotherapy at the clinical site compared with the number of patients that were trial eligible and received radiotherapy at the clinical site during the study period\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Comparison of serum SFRP2 levels before and after preoperative 5-Day HFRT\', \'description\': \'Changes in serum SFRP2 levels before and after preoperative 5-day HFRT and the incidence of favorable pathologic response defined as extent of tumor fibrosis/hyalinization and infarct > 12.5%\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Evaluating patient satisfaction with trial participation\', \'description\': \'Decision Regret Scale questionnaire at the 2-week post radiation visit and the 6-month postoperative visit\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Assessing patient rated importance of short course of radiotherapy in decision to participate in study\', \'description\': \'Patient questionnaire administered at the 2-week post-radiation visit will assess how the patients prioritized the convenience of preoperative 5-day HFRT in making the decision to participate in the study\', \'timeFrame\': \'Up to 3 years\'}]}, \'designModule\': {\'studyType\': \'INTERVENTIONAL\', \'phases\': [\'NA\'], \'designInfo\': {\'allocation\': \'NA\', \'interventionModel\': \'SINGLE_GROUP\', \'primaryPurpose\': \'TREATMENT\', \'maskingInfo\': {\'masking\': \'NONE\'}}, \'enrollmentInfo\': {\'count\': 15, \'type\': \'ESTIMATED\'}}}, {\'officialTitle\': \'Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study\', \'eligibilityModule\': {\'eligibilityCriteria\': \'Inclusion Criteria:\\n\\n1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis.\\n2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma\\n3. Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample.\\n4. Patients aged ≤24 years\\n5. Pathological review of tumor samples.\\n6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional.\\n\\nExclusion Criteria:\\n\\n* 1. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.\', \'healthyVolunteers\': False, \'sex\': \'ALL\', \'maximumAge\': \'24 Years\', \'stdAges\': [\'CHILD\', \'ADULT\'], \'studyPopulation\': \'Children, adolescents and young adults aged ≤ 24 years with newly diagnosed or relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma.\', \'samplingMethod\': \'PROBABILITY_SAMPLE\'}, \'centralContacts\': [{\'name\': \'Elisa Tirtei, MD\', \'role\': \'CONTACT\', \'phone\': \'00390113135171\', \'email\': \'etirtei@cittadellasalute.to.it\'}, {\'name\': \'Celeste Cagnazzo, PhD\', \'role\': \'CONTACT\', \'email\': \'celeste.cagnazzo@unito.it\'}], \'conditions\': [\'Diagnosed or Relapsed/Refractory Sarcomas\'], \'armsInterventionsModule\': {\'interventions\': [{\'type\': \'OTHER\', \'name\': \'observation and biopsy\', \'description\': \'biopsy\'}]}, \'outcomesModule\': {\'primaryOutcomes\': [{\'measure\': \'evaluate the genomic profiles of osteosarcoma, Ewing sarcoma and Synovial Sarcoma tumor samples in pediatric, adolescents and young adult patients at the time of diagnosis or relapse/progression\', \'timeFrame\': \'2018-2021\'}]}, \'designModule\': {\'studyType\': \'OBSERVATIONAL\', \'patientRegistry\': False, \'designInfo\': {\'observationalModel\': \'COHORT\', \'timePerspective\': \'PROSPECTIVE\'}, \'bioSpec\': {\'retention\': \'SAMPLES_WITH_DNA\', \'description\': \'biopsies\'}, \'enrollmentInfo\': {\'count\': 120, \'type\': \'ESTIMATED\'}}}]', raw_output='[{\'officialTitle\': \'Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma\', \'eligibilityModule\': {\'eligibilityCriteria\': \'Inclusion Criteria:\\n\\n1. AJCC 8th edition stage I-III histologically confirmed STS of the extremity or trunk\\n2. Male or female, aged > 18 years old\\n3. ECOG Performance Status 0-3\\n4. Meets screening criteria for receipt of radiotherapy\\n5. Deemed eligible for wide local excision\\n\\nExclusion Criteria:\\n\\n1. Distant metastatic disease\\n2. Prior radiation therapy in the proposed treatment area\\n3. Simultaneous treatment of another malignancy\\n4. Planned neoadjuvant or adjuvant chemotherapy\', \'healthyVolunteers\': False, \'sex\': \'ALL\', \'minimumAge\': \'18 Years\', \'stdAges\': [\'ADULT\', \'OLDER_ADULT\']}, \'centralContacts\': [{\'name\': \'Alan Brisendine\', \'role\': \'CONTACT\', \'phone\': \'843-792-9007\', \'email\': \'brisend@musc.edu\'}, {\'name\': \'Jasmin M Brooks\', \'role\': \'CONTACT\', \'email\': \'brooksjm@musc.edu\'}], \'conditions\': [\'Soft Tissue Sarcoma\'], \'armsInterventionsModule\': {\'armGroups\': [{\'label\': \'Hypofractionated Radiation Therapy\', \'type\': \'EXPERIMENTAL\', \'interventionNames\': [\'Radiation: Hypofractionated Radiation Therapy\']}], \'interventions\': [{\'type\': \'RADIATION\', \'name\': \'Hypofractionated Radiation Therapy\', \'description\': \'Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by "standard of care" wide local excision 2-6 weeks later.\', \'armGroupLabels\': [\'Hypofractionated Radiation Therapy\']}]}, \'outcomesModule\': {\'primaryOutcomes\': [{\'measure\': \'Feasibility of 5-day HFRT\', \'description\': \'The preoperative 5-day HFRT uptake rate, defined as the proportion of eligible patients who elect to participate in the trial.\', \'timeFrame\': \'Up to 3 years\'}], \'secondaryOutcomes\': [{\'measure\': \'Rate of favorable pathologic response\', \'description\': \'Proportion of patients with extent of tumor fibrosis/hyalinization and infarct > 12.5%\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Rate of major wound complication\', \'description\': \'Major wound complication defined according to CAN-NCIC-SR2 Multi-center trial within 6 months of surgery\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Local Control\', \'description\': \'Local control defined as 1-year Local Recurrence Free Survival, calculated from the date of surgery to the date of 12-month follow up\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Acute toxicity\', \'description\': \'Acute toxicity defined by CTCAE v 5.0 assessed during radiotherapy treatment and 2 weeks following completion of radiotherapy\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'1-year late HFRT toxicity\', \'description\': \'Defined by physician assessment using the RTOG/EORTC criteria and the Stern scale for edema\', \'timeFrame\': \'Up to 3 years\'}], \'otherOutcomes\': [{\'measure\': \'Comparison of socio-demographic profiles\', \'description\': \'age, race, gender, marital status, health insurance status, comorbidities, geocode defined rural vs urban residence, estimated distance traveled to HCC, census tract level American Community Survey variables to include Socioeconomic status, Household Composition and Disability, Minority Status and Language, Housing Type, and Transportation\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Comparison of retention rate for radiotherapy at the clinical site\', \'description\': \'number of patients meeting trial eligibility criteria in prior 3 years that received radiotherapy at the clinical site compared with the number of patients that were trial eligible and received radiotherapy at the clinical site during the study period\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Comparison of serum SFRP2 levels before and after preoperative 5-Day HFRT\', \'description\': \'Changes in serum SFRP2 levels before and after preoperative 5-day HFRT and the incidence of favorable pathologic response defined as extent of tumor fibrosis/hyalinization and infarct > 12.5%\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Evaluating patient satisfaction with trial participation\', \'description\': \'Decision Regret Scale questionnaire at the 2-week post radiation visit and the 6-month postoperative visit\', \'timeFrame\': \'Up to 3 years\'}, {\'measure\': \'Assessing patient rated importance of short course of radiotherapy in decision to participate in study\', \'description\': \'Patient questionnaire administered at the 2-week post-radiation visit will assess how the patients prioritized the convenience of preoperative 5-day HFRT in making the decision to participate in the study\', \'timeFrame\': \'Up to 3 years\'}]}, \'designModule\': {\'studyType\': \'INTERVENTIONAL\', \'phases\': [\'NA\'], \'designInfo\': {\'allocation\': \'NA\', \'interventionModel\': \'SINGLE_GROUP\', \'primaryPurpose\': \'TREATMENT\', \'maskingInfo\': {\'masking\': \'NONE\'}}, \'enrollmentInfo\': {\'count\': 15, \'type\': \'ESTIMATED\'}}}, {\'officialTitle\': \'Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study\', \'eligibilityModule\': {\'eligibilityCriteria\': \'Inclusion Criteria:\\n\\n1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis.\\n2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma\\n3. Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample.\\n4. Patients aged ≤24 years\\n5. Pathological review of tumor samples.\\n6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional.\\n\\nExclusion Criteria:\\n\\n* 1. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.\', \'healthyVolunteers\': False, \'sex\': \'ALL\', \'maximumAge\': \'24 Years\', \'stdAges\': [\'CHILD\', \'ADULT\'], \'studyPopulation\': \'Children, adolescents and young adults aged ≤ 24 years with newly diagnosed or relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma.\', \'samplingMethod\': \'PROBABILITY_SAMPLE\'}, \'centralContacts\': [{\'name\': \'Elisa Tirtei, MD\', \'role\': \'CONTACT\', \'phone\': \'00390113135171\', \'email\': \'etirtei@cittadellasalute.to.it\'}, {\'name\': \'Celeste Cagnazzo, PhD\', \'role\': \'CONTACT\', \'email\': \'celeste.cagnazzo@unito.it\'}], \'conditions\': [\'Diagnosed or Relapsed/Refractory Sarcomas\'], \'armsInterventionsModule\': {\'interventions\': [{\'type\': \'OTHER\', \'name\': \'observation and biopsy\', \'description\': \'biopsy\'}]}, \'outcomesModule\': {\'primaryOutcomes\': [{\'measure\': \'evaluate the genomic profiles of osteosarcoma, Ewing sarcoma and Synovial Sarcoma tumor samples in pediatric, adolescents and young adult patients at the time of diagnosis or relapse/progression\', \'timeFrame\': \'2018-2021\'}]}, \'designModule\': {\'studyType\': \'OBSERVATIONAL\', \'patientRegistry\': False, \'designInfo\': {\'observationalModel\': \'COHORT\', \'timePerspective\': \'PROSPECTIVE\'}, \'bioSpec\': {\'retention\': \'SAMPLES_WITH_DNA\', \'description\': \'biopsies\'}, \'enrollmentInfo\': {\'count\': 120, \'type\': \'ESTIMATED\'}}}]'), TaskOutput(description='Using the search results from the Clinical Trials Searcher,\n  curate a list of the most relevant clinical trials to the patient. Review the eligibility\n  requirements of the search results to determine best fit. If any additional context is needed to determine clinical trial eligibility,\n  you may ask the human basic follow up questions about themselves or their condition. For each clinical trial in your list, you \n  will provide the official title, contact info and an explanation on how the patient would be a good fit for the clinical trial.', summary='Using the search results from the Clinical Trials Searcher,\n ...', exported_output='The best clinical trial for the patient is the Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma. The patient meets all of the eligibility criteria and the intervention could be a good fit for their condition as it is a form of radiation therapy followed by surgery. The second clinical trial, Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study, is not a good fit for the patient as they do not meet the age criteria. The final answer is the actual complete content as the final answer, not a summary.', raw_output='The best clinical trial for the patient is the Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma. The patient meets all of the eligibility criteria and the intervention could be a good fit for their condition as it is a form of radiation therapy followed by surgery. The second clinical trial, Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas (SAR-GEN_ITA): a Multicenter Prospective Study, is not a good fit for the patient as they do not meet the age criteria. The final answer is the actual complete content as the final answer, not a summary.')]}